Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the ...

Rani Therapeutics (RANI) announced pharmacokinetic and pharmacodynamic data from a preclinical study evaluating RT-114, a GLP-1/GLP-2 dual ...

(RTTNews) - Biomea Fusion, Inc. (Nasdaq ... Additionally, icovamenib enhanced the effectiveness of GLP-1-based therapies, potentially allowing for lower doses and improved tolerability.

Preoperative use of GLP-1 receptor agonists was not significantly ... bariatric surgery, spinal fusion, tibial and ankle ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce inflammation and improve heart health. With such advantages, the demand ...

Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar.

A large-scale study analyzing data from over 60 million patients finds no evidence that GLP-1 receptor agonists increase suicidality risk in type 2 diabetes patients, challenging previous safety ...

Biomea Fusion (BMEA) announced the presentation of ... and potential as a combination therapy with GLP-1-based medicines. ATTD 2025 Conference Highlights: First Large-Scale Analysis of C-Peptide ...